CRN09682

CRN09682 is a first-in-class, nonpeptide drug conjugate (NDC) developed by Crinetics Pharmaceuticals for the treatment of neuroendocrine tumors (NETs) and other solid tumors that express somatostatin receptor 2 (SST2). Unlike traditional antibody-drug conjugates, CRN09682 uses a highly optimized small molecule G protein-coupled receptor ligand to selectively bind SST2 on tumor cells. Upon binding, it induces internalization and intracellular release of a potent anti-tumor agent—monomethyl auristatin E (MMAE)—which acts as a tubulin polymerization inhibitor. This design aims to enhance tumor penetration and minimize systemic toxicity. The drug is manufactured via traditional chemical synthesis rather than biologic methods required for antibodies. Preclinical studies have demonstrated potent and selective anti-tumor activity in SST2-expressing models with favorable pharmacokinetics and safety profile. As of mid-2025, CRN09682 has received IND clearance from the FDA to begin Phase 1/2 clinical trials in patients with metastatic or locally advanced SST2-positive neuroendocrine tumors and other SST2-expressing solid tumors[4][6][8].

Other names

CRN09682CRN-09682CRN 09682